Olaparib Oral Capsule
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancers Harbouring Mutations in HRG
Conditions
Advanced Cancers Harbouring Mutations in HRG
Trial Timeline
Feb 7, 2019 → Dec 31, 2025
NCT ID
NCT03967938About Olaparib Oral Capsule
Olaparib Oral Capsule is a phase 2 stage product being developed by AstraZeneca for Advanced Cancers Harbouring Mutations in HRG. The current trial status is active. This product is registered under clinical trial identifier NCT03967938. Target conditions include Advanced Cancers Harbouring Mutations in HRG.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancers Harbouring Mutations in HRG were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03967938 | Phase 2 | Active |
Competing Products
20 competing products in Advanced Cancers Harbouring Mutations in HRG